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Abstract
Background: Myogenic temporomandibular disorders (MTMD) frequently coexist with other clinical conditions 
in the same individual. In the last decades, several authors have analyzed these comorbidities looking for the ori-
gin of this overlapping. 
Objetives: The aim of this study was to perform a comparative anaylisis between a group of patients with MTMD 
and a control group of dental patients without dysfunctional pathology to assess whether there are significant dif-
ferences in the presence of systemic medical comorbidities between the two groups.
Material and Methods: Restrospective epidemiological analysis, based on medical questionnaires in a group of 31 
patients, women, aged from 24 to 58 (average 39.96 years), diagnosed with MTMD (Masticatory Myofascial Pain), 
with a control group with the same number of individuals, gender and age range to evaluate if there is a significant 
statistical difference in the presence of medical comorbidities in this group of patients with MTMD and if they are 
in a higher risk of suffering different pathological conditions. 
Results: It was found that the group affected by MTMD presented many more associated medical conditions 
than the control group: health changes during the last year, medical evaluations and treatments, presence of pain, 
sinus disease, tinnitus, headache, joint pain, ocular disorders, fatigue, dizziness, genitourinary disorders and 
xerostomia among others; and they were also in a higher risk to suffer other pathological entities as headaches 
and articular pain. 
de-Pedro-Herráez M, Mesa-Jiménez J, Fernández-de-las-Peñas C, de-
la-Hoz-Aizpurua JL. Myogenic temporomandibular disorders: Clinical 
systemic comorbidities in a female population sample. Med Oral Patol 
Oral Cir Bucal. 2016 Nov 1;21 (6):e784-92.   
 http://www.medicinaoral.com/medoralfree01/v21i6/medoralv21i6p784.pdf
Article Number: 21249          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.21249
http://dx.doi.org/doi:10.4317/medoral.21249
Med Oral Patol Oral Cir Bucal. 2016 Nov  1;21 (6):e784-92.                                                                                                                                            Comorbidity in temporomandibular disorders
e785
Conclusions: These results reinforce our hypothesis that MTMD belong to a group of medical conditions triggered 
by a loss of equilibrium of the individual’s Psycho-Neuro-Endocrine-Immune (PNEI) Axis that produces alterations 
in the response against external stimuli in some genetically predisposed individuals. It is, therefore, necessary to 
change the way of diagnosing and managing these individual’s medical conditions, being mandatory to look from a 
more multidisciplinary perspective than the one we are currently offering.
 Key words: Temporomandibular joint disorders, myofascial pain syndromes, comorbidity, chronic pain, health 
status, health questionnaire, self report.
Introduction
Temporomandibular Disorders (TMDs) is a general term 
that includes a group of clinical conditions affecting the 
temporomandibular joint, the masticatory musculature 
and associated head and neck musculoskeletal struc-
tures. It affects 5-12% of the general population and is 
the second most frequent cause of musculoskeletal pain 
and limitation, only preceeded by low back pain. Myo-
fascial Pain is the most prevalent TMD diagnosis and 
it is defined as “pain of muscle origin that is affected 
by jaw movement, function, or para-function, and rep-
lication of this pain occurs with provocation testing of 
the masticatory muscles spreading beyond the site of 
palpation but within the boundary of the muscle when 
using myofascial examination protocol” (1). Myofascial 
pain syndrome can be described as the sensory, motor 
and autonomic symptoms caused by myofascial trigger 
points. A myofascial trigger point is defined as a hyper-
irritable spot in a taut band of a skeletal muscle. The 
sensitive spot is painful on compression and can give 
rise to characteristic referred pain, referred tenderness, 
motor dysfunction and autonomic phenomena (2).
Myofascial TMD frequently coexists with other clinical 
entities (1,3). The OPPERA study concluded that people 
with a history of lower back pain at enrollment had a 
50% greater incidence of TMD than people without his-
tory of low back pain; a history of genital pain symptoms 
was associated with 75% greater incidence of develop-
ing TMD; whereas irritable bowel syndrome predicted 
first-onset TMD after adjustment for demographic 
characteristics and pain disorders (3). Several names are 
used to describe this type of comorbidities:  Medically 
Unexplained Symptoms, Unexplained Clinical Condi-
tions (4), Functional Somatic Syndromes, Somatization 
Disorders, Polysymptomatic Somatizers, Somatization 
Spectrum Conditions, Psychosomatic Syndromes, Idi-
opathic Pain Disorders (5). Consequently, several au-
thors have agreed to use the term Central Sensitivity 
Syndromes (6,7), including different systemic diseases 
such as fibromyalgia, TMD, bowel problems, urogenital 
problems, headaches or chronic pain in different body 
areas (7).
The aim of this paper is to analyze the relationship of 
Masticatory Myofascial Pain (MTMD) with other sys-
temic conditions by means of an epidemiological retro-
spective cohort study.
Material and Methods
Procedure: This epidemiological retrospective cohort 
study based on health questionnaires was conducted in 
2015, about four years after the initial evaluation of the 
patients at the Dental Clinic of the University San Pab-
lo-CEU in Madrid. The research project was approved 
by the Ethical Committee of the Master in OFP & TMD 
and all patients signed an Informed Consent Document. 
The study  was conducted from the 66 variables (Table 
1) in the general health questionnaires of the medical 
history: general health, changes in general health in the 
last year, hospitalization in the last three years, present 
treatments, problems with prior dental treatments, 
present pain complaint, chest pain / angina, swollen 
ankles, fatigue, weight loss / night sweats, persistent 
or bloody cough, coagulation problems, sinusitis, dif-
ficulty swallowing, frequent nausea/vomiting, diarrhea 
/ constipation / fecal blood, difficult urination / bloody 
urine, dizziness / vertigo, ringing in the ears, headaches 
/ migraines, loss of consciousness, blurred vision, ex-
cessive thirst, frequent urination, dry mouth, jaundice, 
joint pain, stiffness, heart disease, heart attacks, cardiac 
birth defects, rheumatic fever, high blood pressure, tu-
berculosis / emphysema / other lung diseases, hepatitis 
/ liver disease, stomach / ulcers, allergies, family prob-
lems of diabetes, heart disease or tumors, AIDS, tumors 
/ cancer, arthritis / rheumatism, eye diseases, skin dis-
eases, anemia, syphilis / gonorrhea, herpes, kidney dis-
ease, thyroid disease, diabetes, psychiatric treatment, 
radiotherapy, chemotherapy, artificial heart valves, joint 
prostheses, hospitalization, blood transfusions, surgery, 
pacemakers, contact lenses, drug abuse, medication 
use, smoking, alcohol consumption, current pregnancy, 
contraceptive use and other medical problems.
Sample: The study group was composed of 120 Health 
Questionnaires of female patients who fulfilled the 
RDC/TMD criteria of myofascial pain (1). We excluded 
men from the study because the majority of patients 
affected by MTMD are women (3-7). Only complete 
and validated or confirmed by medical reports by cor-
responding complementary analytical test Health Ques-
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tionnaires were included in this study, excluding those 
that were incomplete or contained any illegible answer 
and obtaining a from total of 43 patients who met all 
requirements. On the other hand, we selected another 
43 Health Questionnaires of female patients who came 
to the university clinic for general dental practices (also 
meeting these criteria of validation and analytical con-
firmation) for the control group (Fig. 1).
Once the two initial groups (study and control) were 
selected, we performed the standard deviations of the 
total number of patients and of the two subgroups tak-
ing the age as variable. The average age in the MTMD 
group was 38.67 years, while in the control group it was 
41.25 years, with a total average of 39.96 years for both 
groups. Within the standard deviation between 24 and 
58 years old there were 31 patients in the TMD group 
and 26 in the control group. Patients that were not in this 
range were excluded from the study. We finally added 5 
patients to the control group to equalize both groups in 
31 subjects between 24 and 58 years.
Measures: All patients included in the MTMD group 
fulfilled the diagnostic criteria of the RDC/TMD (1) 
and also the Gerwin criteria for the diagnosis of myo-
fascial trigger points (8) (Table 2).
Statistical analysis:  Analysis of the relationship between 
all the qualitative variables and the group to which the 
individual belonged (MTMD or control group) was 
made to check whether there was a disproportion be-
tween the different categories of qualitative variables 
depending on the group of the individual using chi-
square test of the SPSS program v. 2.0, performing con-
tingency tables to cross each of the variables with the 
group variable (null hypothesis was proposed as inde-
pendence between the variables and the group) to obtain 
the contrast p-value. It was considered that there were 
significant imbalances when p-values were less than 
0.05; working, therefore with 95% confidence rate. Odd 
Ratio (OR) was also calculated to assess the risk estima-
tion of the different variables in both groups.
VARIABLES IN THE HEALTH QUESTIONNAIRE
General Health Changes in Health Hospitalization last 3 years Present treatment
Previous Health Problems Present Pain Chest Pain                           Swollen Ankles
Fatigue Night Sweating Persistent Cough Coagulation Problems
Sinusitis Dificulty Swallowing Nausea/Vomiting Diarrhea/Constipation                     
Difficulty Urinating Dizziness/Vertigo Ringing in the ears/Tinnitus Headaches
Loss of Conciousness Blurred Vision Excessive Thirst Frequent Urination
Dry Mouth/Xerostomia Jaundice Joint Pain Joint Stiffness
Heart Disease Heart Attacks Congenital Heart Disease Rheumatic Fever
High Blood Pressure Lung Disease Liver Disease Stomach Problems
Allergies Family Problems AIDS Tumors/Cancer
Arthritis/Rheumatism Eye Diseases Skin Disease Anemia
Syphilis/Gonorrhea Herpes Kidney Disease Thyroid Disease
Diabetes Psyquiatric Treatment Radiotherapy Chemotherapy
Artificial Heart Valves Joint Prostheses Hospitalization Blood Transfussions
Surgery Pacemaker Contact Lenses Drugs Abuse
Use of Medications Tobacco Alcohol Pregnancy
Contraceptives Other Medical Problems
Table 1. Procedures: variables in the health questionnaire.
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             RDC/TMD  MYOFASCIAL PAIN(1)  GERWIN TRIGGER POINT CRITERIA(8)
Pain in the jaw, temple, in the ear, or in front of ear. Take the patient’s history and use a pain drawing to                    identify pain locations.
Pain modified with jaw movement, function  or                               
or parafunction.
Palpate the muscle for taut bands, using either flat                         
palpation or pincer palpation and move the fingers                         
along the taut band to find the trigger point.
Confirmation of pain locations in the temporalis or              
masseter masseter muscle. Compress the trigger point manually.
Report of familiar pain with palpation of the                            
temporalis or masseter muscle. Positive sensation of pain away from the trigger point.
Report of pain spreading beyond the site of palpation       
but within the boundary of the muscle.
Table 2. Measures: diagnostic criteria MTMD group.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 Questionnaires 
fulfilling RDC/TMD & 
Gerwin Criteria 
43 Questionnaires 
MTMD Group 
43 Quetionnaires 
Control Group 
31 Questionnaires MTMD 
Group 
26 Questionnaires 
ControlGroup 
31 Questionnaires Control 
Group 
Normal Deviation 
Add 5 patients to 
Control Group 
Eliminate incomplete or 
illegible 
Fig. 1. Sample.
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Results
In the vast majority of variables, the patients in the 
study group (MTMD) suffered more medical comor-
bidities. Ten variables with statistical significance be-
tween both groups were found (Fig. 2): health changes 
during the last year (22.6% MTMD vs 0% control. 
p=0.005), present medical treatment (41.9% MTMD 
vs 9.7% control. p=0.004), present pain (77.4% MTMD 
vs 29%  control P<0.001), sinusitis (25.8%  MTMD vs 
6.5% control. p=0.040), tinnitus (51.6% MTMD vs 9.7% 
control. P<0.001), headaches (61.3% DCM vs 19.4% 
control. p=0.001), joint pain (54.8% MTMD vs 19.4% 
control. p=0.004), joint stiffness (35.5% MTMD vs 
9.7% control. p=0.016), eye disease (12.9%  MTMD vs 
0% control. p=0.050) and contact lenses (38.7% MTMD 
vs 16.1% control. p=0.043) (Table 3)
Important, though not statistically significant, dif-
ferences were observed in another 7 variables (Fig. 
3): fatigue (25.8% MTMD vs 9.7% control. p=0.091), 
dizziness and vertigo (29%  MTMD vs 19.4% control. 
p=0.277), poliuria/frequent urination (29% MTMD vs 
16.1% control. p=0.181), xerostomia/dry mouth  (25.8 
% MTMD vs 12.9% control. p=0.168), other medical 
conditions (19.4% MTMD vs 9.7% control. p=0.236), 
smoking (29%  MTMD vs 12.9% control. p=0.106) y 
alcohol consumption (9.7% MTMD vs 3.2% control. 
p=0.306) (Table 4).
Finally, after analyzing the OR, it was found that 
MTMD patents where in a higher risk of being under 
a higher number of medical treatments (OR 6.741), suf-
fered more pain (OR 8.381), sinusitis (OR 5.043), tin-
nitus (OR 9.956), headaches (OR 6.597), joint pain (OR 
5.060) and joint stiffness (OR  5.133).
Discussion
Our results support the hypothesis that MTMD patients 
are at greater risk of suffering other medical conditions 
than the healthy population, which is in agreement with 
previous studies (9-12). We found 10 health variables 
showing statistical difference between the MTMD 
Group and the Control Group. The variable health 
changes during the last year includes patients diagnosed 
with a new medical condition or worsening of a prior 
existing condition confirmed by their physician and/or 
analytical report; this was present in 22.6% of patients 
in the MTMD Group versus none (0%) in the Control 
Group. Almost half (41.9%) of the MTMD patients were 
presently receiving another medical treatment versus 
9.7% in the Control Group. This confirms the fact that 
MTMD is usually comorbid with other medical condi-
tions (4,7,9-12) as fibromyalgia or chronic fatigue syn-
drome (6,8). 77,4% MTMD patients had present pain 
vs. 29% the Control Group; these data are very similar 
to those of Aaron et al. (9) and Hoffmann et al. (11). 
25.8% of MTMD patients had a diagnosis of sinusitis 
(according to the Diagnostic Criteria of the ICHD-3β: 
11.5.1: Headache attributed to Acute Rhinosinusitis 
(13), against a 6.5% of the Control Group; Charleston et 
al. (14) state the existence of possible pathophysiologi-
cal interactions between MTMD and sinusitis, due to a 
hypersensitivity to external stimuli secondary to CNS 
sensitization (orofacial musculature and paranasal si-
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Fig. 2. Distribution of medical conditions with statistical differences.
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MEDICAL CONDITIONS WITH STATISTICAL DIFFERENCES
PATHOLOGY GROUP n % P VALUE ODDS RATIO
HEALTH CHANGES
 LAST YEAR
MTMD
CONTROL
7
0
22.6
0 0.005
PRESENT TREATMENT MTMDCONTROL
13
3
41.9
9.7 0.004 6.741
PRESENT PAIN MTMDCONTROL
24
9
77.4
29 0.000 8.381
SINUSITIS MTMDCONTROL
8
2
25.8
6.5 0.040 5.043
TINNITUS MTMDCONTROL
16
3
51.6
9.7 0.000 9.956
HEADACHES MTMDCONTROL
19
6
61.3
19.4 0.001 6.597
JOINT PAIN MTMDCONTROL
17
6
54.8
19.4 0.001 5.060
JOINT STIFFNESS MTMDCONTROL
11
3
35,5
9.7 0.016 5.133
EYE DISEASES MTMDCONTROL
4
0
12.9
0 0.050
CONTACT LENSES MTMDCONTROL
12
5
38.7
16.1 0.043 3.284
Table 3. Medical conditions with statistical differences.
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Fig. 3. Distribution of other medical conditions.
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nuses share a common innervation via V1, V2 and the 
sphenopalatine ganglion). More than half (51.6%) of the 
MTMD patients referred the presence of tinnitus com-
pared with 9.7% in the Control Group; these figures are 
comparable with those of other similar studies (9-12). 
Tinnitus is described as “the subjective perception of 
sound in the absence of apparent acoustic stimuli” (15) 
and can be caused by otologic, neurological, traumatic, 
medicinal, nutritional, depressive and origin myogenic 
craniomandibular dysfunction pathologies according 
to Calderon et al. (15) These authors did not find any 
agreement among the different etiopathological hypoth-
esis, but stating that tinnitus and chronic pain produce 
similar alterations in the Central and Peripheral Nervous 
System due to neuroplasticity and central sensitization. 
Teachey et al. (16), claim that there is a direct influence 
of MTMD in the presence of tinnitus due to the pres-
ence of myofascial trigger points in masseter and es-
ternocleidomastoid muscles that improve with adequate 
physical therapy treatment of these trigger points. 61.3% 
of MTMD patients complain of Headache (19,4% in the 
Control Group). Headache diagnosis is made accord-
ing to the ICHD-3β (13) for primary headaches (1,2,3,4 
ICHD-3β) or those attributed to TMD (11.7 ICHD-3β). 
In 2013, Da silva et al. (17) stated that “TMD are an im-
portant comorbidity of migraine and may be clinically 
difficult to distinguish them from tension-type head-
ache” (17). According to these authors, 50% of the pop-
ulation suffers from headache at some point in their life 
and TMD affects 40-60%, confirming the comorbidity. 
Articular Pathology: 54.8% MTMD vs 19.4% Control 
Group suffer Joint (Articular) Pain, and 35.% MTMD 
vs 9.7% Control Group feel Joint Stiffness. We included 
in this group those patients fulfilling the RDC/TMD 
Criteria of Artralgia and Myogenic TMD (1) and those 
with a written medical report regarding this pathology: 
Inoue et al. support the hypothesis that there is comor-
bidity between MTMD and TMJ Artralgia (18). Sipila et 
al. conclude that “masticatory muscle pain is associated 
with pain in the back, neck, shoulders, and other joints 
due to central sensitization” (19). Eye Disease: 12.9% 
of MTMD suffer from Eye Disease (with confirmed 
medical diagnosis) vs. 0% in the Control Group. 38.7% 
of MTMD patients use prescription glasses or contact 
lenses vs. 16.1% in the Control Group: Monaco et al. 
propose that this is due to an alteration of propriocep-
tion in the cervical muscles (20).
We have also found important, though not statistically 
significant, differences between both groups in some 
other variables: Fatigue, 25,8% vs. 9,7%. Chronic Fa-
tigue Syndrome  and  Fibromyalgia (with medical con-
firmed diagnosis) were included in this group as they 
have been confirmed in many other studies (5,7,9-12-
,15,16,21). In 2012, Da Silva et al. presented a case con-
trol study to analyze the prevalence of orofacial pain 
in fibromyalgia patients. The conclusion was that the 
comorbidity between TMD and fibromyalgia is due to 
central sensitization, with high levels of substance P 
and growth factor causing a compromise in thalamic 
function (21). That same year, Fraga et al. concluded 
that MTMD should be included as diagnostic criteria 
in fibromyalgia (22). 29% of MTMD patients refer the 
presence of Dizziness/Vertigo vs 19.4% in the control 
group. Hubbard considers that these symptoms are due 
to cervical proprioceptive stimuli and they may be ad-
dressed with the therapeutic management of the head 
and neck trigger points (23). As it is shown in similar 
studies (9-12), genitourinary symptoms (chronic pelvic 
                                                            OTHER MEDICAL CONDITIONS
PATHOLOGY GROUP n % P VALUE ODDS RATIO
FATIGUE MTMDCONTROL
8
3
25.8
9.7 0.091 3.246
DIZZINESS MTMDCONTROL
9
6
29
19.4 0.227 1.702
POLYURIA MTMDCONTROL
9
5
29
16.1 0.181 2.127
XEROSTOMIA MTMDCONTROL
8
4
25.8
12.9 0.168 2.348
OTHER MEDICAL 
CONDITIONS                                
MTMD
CONTROL
6
3
19.4
9.7 0.236 2.240
TOBACCO MTMDCONTROL
9
4
29
12.9 0.106 2.761
ALCOHOL MTMDCONTROL
3
1
9.7
3.2 0.306 3.214
Table 4. Other medical conditions.
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pain, interstitial cystitis, painful bladder syndrome and 
vulvodynia (24) are more prevalent (29%) in MTMD 
patients than in the control group. Rodríguez et al. in 
2009 concluded that 13% of patients with TMD also 
suffer from cystitis and 20% of patients with vulvody-
nia present muscular pain (24). 25.8% MTMD patients 
refer xerostomia vs 12.9% in the control group. Xeros-
tomia is defined as that “sense of lack of saliva, which 
may or may not coincide with the actual salivary flow 
volume” (25). According to Da Silva et al., the volume 
of salivary flow in TMD patients is compromised due 
to central sensitization, hypothalamic function com-
promise or secondary to the pharmacologic treatment 
used in these patients (25). Smoking (more than 100 
cigarettes a week): 29% of MTMD patients smoke in 
comparison with 12.9% in the control group (26). De 
Leeuw et al. included smoking as one of the main co-
morbidities of TMD (12) and so did the OPPERA Study 
(3). Burris et al. have recently confirmed that tobacco is 
statistically related to pain and psychological function-
ing of patients, causing increased fatigue and adversely 
affecting pain experience and quality of sleep (26).
It seems that the relation among all these pathologies 
goes well beyond that of functional neurological com-
promise or pain perception. Some other factors, as an 
excess of histamine (27) or the role of Na+ channels, 
especially Nav 1.9 in bowel function and orofacial pain 
have a significant influence. These channels are found 
in the soma of small and medium size peripheral neu-
rons and in afferent fibers of the lip and dental pulp, 
showing the close relation between gastrointestinal 
syndromes and trigeminal pain (28). The relationship 
between Nav 1.7 and Nav 1.8 Na+ channels and chronic 
pain is presently a matter of research interest as well. 
Some mutations and phenotype variations are related 
with a higher expression of pain sensation (for example, 
the enzyme COMT contains at least five functional pol-
ymorphisms that significantly affect its activity (28,29). 
Scientific evidence is showing that all these entities (ir-
ritable bowel syndrome, interstitial cystitis, dyspepsia, 
fibromyalgia, TMD, chronic fatigue syndrome, among 
others) share common pathophysiological mechanisms 
leading to an altered pain perception (2,4-12,23,24,28-
30) and cerebral activation models (29), peripheral im-
munity activation (4,27-30), post-infectious factors (29), 
neuroendocrine dysregulation (2,4-12,28-30) and ge-
netic influence (28-30). 
Other authors as Ablin and Clauw state that the main 
reason for the existence of these comorbidities and 
chronic pain syndromes is the disruption of the equi-
librium of the PsychoNeuroEndocrineImmune Axis in 
genetically predisposed patients due to the influence of 
various stressing factors, proposing the concept of Cen-
tral or Centralized Pain (30). 
Our study has several limitations: the group size is 
smaller than in other similar studies (9-12), the ques-
tionnaire used for the study may not be the most specific 
for certain type of pathologies as functional digestive 
disorders and the population of the study is mainly (but 
not all) from downtown Madrid. It would be interest-
ing to perform a multicentre study with a broader geo-
graphic distribution. 
The analysis and discussion of our results with the 
appropriate literature allows us to formulate the Con-
clusion that MTMD belongs to a group of clinical enti-
ties that have in common the alteration of the functio-
nal equilibrium of the PsychoNeuroEndocrineImmune 
Axis in genetically predisposed individuals.
Conclusions
The main conclusions of our study are:
1. Patients with MTMD present a higher number of 
medical comorbidities (present pain, sinusitis, tinnitus, 
joint pain, eye disease fatigue, vertigo/dizziness, func-
tional genitourinary disorders, xerostomia) than the 
general population.
2. In these patients, these pathologies seem arise from 
the loss of functional equilibrium of the PNEI Axis due 
to a variety of stress factors. There seems to be a genetic 
predisposition to this sensitivity.
3. The relationship among all these pathologies seems to 
go beyond the mere presence of pain o the involvement 
of central sensitization but they should be included in 
the group of Central Sensitivity Syndromes, a collec-
tive term embracing a group of clinical problems that 
reflect the loss of equilibrium of the PsychoNeuroEndo-
crineImmune Axis in genetically predisposed sensitive 
individuals. Those individuals would present hypersen-
sitivity in the reaction to a variety of internal or external 
stimuli that attempt to alter the homeostatic equilibrium 
of the human organism.
4. To correctly address these entities a paradigm shift 
is necessary to broaden the medical scope of diagnosis 
and treatment from the ancient mechanistic model to a 
modern interdisciplinary biopsychosocial approach.
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